Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591654 | 0.89 | OPRD1 (0.52) | OPRD1OPRM1 | |
| Hydrochloric Acid SCHEMBL11059956 | 0.86 | OPRD1 (0.64) | OPRD1OPRM1 | |
| SCHEMBL31258335 | 0.86 | CXCL8 (0.53) | OPRD1CXCL8 | |
| SCHEMBL29930217 | 0.84 | CXCL8 (0.56) | OPRD1OPRM1CXCL8 | |
| SCHEMBL31612359 | 0.84 | OPRM1 (0.56) | OPRD1OPRM1 | |
| SCHEMBL29899126 | 0.82 | ACE (0.55) | OPRM1 | |
| SCHEMBL11065220 | 0.82 | OPRM1 (0.66) | OPRD1OPRM1 | |
| SCHEMBL31612385 | 0.82 | OPRM1 (0.61) | OPRD1OPRM1 | |
| SCHEMBL11335332 | 0.81 | OPRM1 (0.60) | OPRD1OPRM1CXCL8 | |
| Acetic Acid SCHEMBL11326955 | 0.81 | OPRM1 (0.65) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594263-B2 | CBL inhibitors and compositions for expansion of immune cells | NURIX THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250022417-A1 | DISPLAY DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-12121540-B2 | CBL inhibitors and compositions for use in adoptive cell therapy | NURIX THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4034141-A1 | CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS | Nurix Therapeutics, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4034140-A1 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | Nurix Therapeutics, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114786687-A | Cbl inhibitors and compositions for adoptive cell therapy | 纽力克斯治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114761027-A | Cbl inhibitors and compositions for immune cell expansion | 纽力克斯治疗公司 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594263-B2 | CBL inhibitors and compositions for expansion of immune cells | CBLC, CBL, CBLB | OPRD1 3186/4885OPRM1 3610/4885CXCL8 1558/4885 |
| US-12121540-B2 | CBL inhibitors and compositions for use in adoptive cell therapy | CBL, CBLB, CBLC | OPRD1 4710/4885OPRM1 4689/4885CXCL8 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.